<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02101515</url>
  </required_header>
  <id_info>
    <org_study_id>13D.590</org_study_id>
    <nct_id>NCT02101515</nct_id>
  </id_info>
  <brief_title>Randomized Control Trial of Second Stage of Labor</brief_title>
  <official_title>Randomized Control Trial of Usual Labor Versus Extended Second Stage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis of this study is that extending the second stage of labor beyond current ACOG
      suggestions can reduce the cesarean delivery rate. The cesarean delivery rate in the United
      States is around 30 percent. This is a number that continues to be increasing over the last
      few decades and will continue to climb. Each subsequent cesarean section puts the mother and
      baby at increased risk for postpartum hemorrhage, bowel and bladder injury, abnormal
      placentation, febrile morbidity and death. The most common reason for a cesarean delivery is
      a repeat cesarean delivery. One way to reduce this number is to prevent the first cesarean
      delivery. The aim of this study is evaluate if extending the second stage of labor affects
      the cesarean delivery rate and subsequent perinatal morbidity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Consent at the time of admission or in the office

        2. 2nd stage starts at full dilation

        3. Randomization occurs at 2 hours without epidural or 3 hours with epidural, stratified by
           epidural status

        4. Randomization scheme is according to a predetermined computer-generated block
           randomization scheme with block sizes of 6,8 and12 (random blocks).

        5. Sequentially numbered and sealed opaque envelopes prepared according to the
           randomization scheme and delivered to a secure container in labor and delivery suite to
           maintain concealed treatment allocation.

        6. At the 3 hour mark, the next number envelope is pulled and opened by the physician/nurse
           to reveal the designated group. At this point the patient is considered randomized.

        7. Provider preference for cesarean delivery, operative vaginal delivery, continued
           pushing, with intention-to-treat analysis

        8. Those that require cesarean delivery - usual perioperative management

        9. Early termination criteria: emergency cesarean delivery, category 3 fetal heart tracing
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cesarean Delivery Rate</measure>
    <time_frame>At time of delivery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>postpartum hemorrhage</measure>
    <time_frame>at time of delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cord pH</measure>
    <time_frame>at time of delivery</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Operative vaginal delivery</measure>
    <time_frame>at time of delivery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>NICU admission</measure>
    <time_frame>at time of delivery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Transfusion</measure>
    <time_frame>at time of delivery until maternal discharge, usually &lt; 5 days</time_frame>
    <description>Any transfusion of packed red blood cells to the mother or any other blood products given.</description>
  </other_outcome>
  <other_outcome>
    <measure>Chorioamnionitis</measure>
    <time_frame>at time of delivery</time_frame>
    <description>Clinical diagnosis of Chorioamnionitis of the mother</description>
  </other_outcome>
  <other_outcome>
    <measure>Endometritis</measure>
    <time_frame>at time of delivery until maternal discharge, usually &lt; 5 days</time_frame>
    <description>Clinical diagnosis of postpartum Endometritis of the mother</description>
  </other_outcome>
  <other_outcome>
    <measure>Laceration</measure>
    <time_frame>at time of delivery</time_frame>
    <description>3rd or 4th degree laceration or cervical laceration diagnosed at delivery.</description>
  </other_outcome>
  <other_outcome>
    <measure>Neonatal Sepsis</measure>
    <time_frame>until neonatal discharge, usually &lt; 5 days</time_frame>
    <description>Diagnosed by neonatology</description>
  </other_outcome>
  <other_outcome>
    <measure>Birth weight</measure>
    <time_frame>at time of delivery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Neonatal seizures</measure>
    <time_frame>until discharge, usually &lt; 5 days</time_frame>
    <description>Diagnosed by neonatology</description>
  </other_outcome>
  <other_outcome>
    <measure>Neonatal length of stay</measure>
    <time_frame>until neonatal discharge, usually &lt; 5 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Shoulder dystocia</measure>
    <time_frame>at time of delivery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Neonatal mortality</measure>
    <time_frame>early neonatal mortality (within 7 days of birth).</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>CPAP or greater</measure>
    <time_frame>Until neonatal discharge, usually &lt; 5 days</time_frame>
    <description>As per NICU</description>
  </other_outcome>
  <other_outcome>
    <measure>Spontaneous vaginal delivery</measure>
    <time_frame>at time of delivery</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Labor Complications</condition>
  <arm_group>
    <arm_group_label>Usual Labor</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Immediate delivery after 3 hours with epidural or 2 hours without epidural</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Extended</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Immediate delivery after 4 hours with an epidural or 3 hours without an epidural
Intervention: one additional hour for the second stage of labor
Length of second stage in extended arm is 3 hours without epidural and 4 hours with epidural.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Length of Second Stage</intervention_name>
    <description>The experimental group will have one additional hour in the second stage of labor</description>
    <arm_group_label>Usual Labor</arm_group_label>
    <arm_group_label>Extended</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Nulliparous women

          -  singleton pregnancies

          -  cephalic presentation

          -  36.0-41.6 weeks

          -  age 18 and older

        Exclusion Criteria:

          -  Category 3 fetal heart tracing

          -  major congenital anomalies

          -  multiples

          -  planned cesarean delivery

          -  intrauterine fetal demise

          -  TOLAC
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexis Gimovsky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vincenzo Berghella, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thomas Jefferson University Hosptial</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2014</study_first_submitted>
  <study_first_submitted_qc>March 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2014</study_first_posted>
  <last_update_submitted>September 25, 2015</last_update_submitted>
  <last_update_submitted_qc>September 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Thomas Jefferson University</investigator_affiliation>
    <investigator_full_name>alexis gimovsky</investigator_full_name>
    <investigator_title>Fellow in Maternal Fetal Medicine</investigator_title>
  </responsible_party>
  <keyword>randomized controlled trial</keyword>
  <keyword>labor complications</keyword>
  <keyword>cesarean section</keyword>
  <keyword>second stage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obstetric Labor Complications</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>September 21, 2016</submitted>
    <returned>November 14, 2016</returned>
    <submitted>November 14, 2016</submitted>
    <returned>January 11, 2017</returned>
    <submitted>March 23, 2017</submitted>
    <returned>May 3, 2017</returned>
    <submitted>January 22, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

